Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus and the associated desensitisation of insulin signalling has been identified as a risk factor for progressive neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and others. Glucagon‐like peptide 1 (GLP‐1) is a hormone that has growth factor‐like and neuroprotective properties. Several clinical trials have been conducted, testing GLP‐1 receptor agonists in patients with Alzheimer's disease, Parkinson's disease or diabetes‐induced memory impairments. The trials showed clear improvements in Alzheimer's disease, Parkinson's disease and diabetic patients. Glucose‐dependent insulinotropic polypeptide/gastric inhibitory peptide (GIP) is the ‘sister’ incretin hormone of GLP‐1. GIP analogues have shown neuroprotective effects in animal models of disease and can improve on the effects of GLP‐1. Novel dual GLP‐1/GIP receptor agonists have been developed that can enter the brain at an enhanced rate. The improved neuroprotective effects of these drugs suggest that they are superior to single GLP‐1 receptor agonists and could provide disease‐modifying care for Alzheimer's disease and Parkinson's disease patients. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“cardiovascular causes in the liraglutide group (Marso et al., 2016).”
BackgroundInflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“It plays important physiological signalling roles to control cell metabolism and energy utilisation (Baggio & Drucker, 2007).”
BackgroundNeuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 3×
“…observation, impaired insulin signalling in the brains of people with Alzheimer's disease or Parkinson's disease had been identified (Athauda & Foltynie, 2016; Cheong et al., 2020; Craft, 2005; Freiherr et al., 2013; Hölscher, 2011; Moroo et al., 1994; Steen et al., 2005; Talbot et al., 2012).”
BackgroundGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“Another very popular and effec- tive drug class is the glucagon-like peptide 1 (GLP-1) receptor agonist group that currently has several different drugs on the market for the treatment of type 2 diabetes mellitus (Dhillon, 2018; Müller et al., 2019; Schmidt et al., 2014).”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 3×
“…observation, impaired insulin signalling in the brains of people with Alzheimer's disease or Parkinson's disease had been identified (Athauda & Foltynie, 2016; Cheong et al., 2020; Craft, 2005; Freiherr et al., 2013; Hölscher, 2011; Moroo et al., 1994; Steen et al., 2005; Talbot et al., 2012).”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 4×
“Unfortunately, there are few studies that measure levels of such drugs in the CSF in humans to estimate the BBB penetrations.”
BackgroundMethodInfluentialPotential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867 · cited 1×
“BDNF can protect synapses in a range of neurodegen- erative disorders (Allen et al., 2013; Blurton-Jones et al., 2009; Nagahara & Tuszynski, 2011).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Kellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820 · cited 1×
“BDNF can protect synapses in a range of neurodegen- erative disorders (Allen et al., 2013; Blurton-Jones et al., 2009; Nagahara & Tuszynski, 2011).”
BackgroundFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764 · cited 2×
“The i.c.v. streptozotocin (STZ) rat model of insulin desensitisation in the brain is considered to be a model of sporadic Alzheimer's disease (Lester-Coll et al., 2006; Moloney et al., 2010; Steen et al., 2005; Talbot et al., 2012).”
BackgroundMcClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Self-citationUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 4×
“Several novel dual agonists have been tested in clinical trials in patients with type 2 diabetes mellitus and some show better effects when compared with single GLP-1 receptor agonists (Finan et al., 2013; Frias et al., 2017, 2018).”
BackgroundInfluentialLi, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 4×
“Exendin-4 had similar protective effects in the MPTP mouse model of Parkinson's disease (Kim et al., 2009; Li et al., 2009).”
BackgroundInfluentialArakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 1×
“…can reduce monocyte adhe- sion to the aortic endothelium in an inflammation response in athero- sclerosis and also prevents lipopolysaccharide (LPS)-induced cytokine and chemokine release (Arakawa et al., 2010) and can prevent an increase in microvascular permeability (Dozier et al., 2009).”
BackgroundExenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 1×
“…able to normalise neuronal progenitor cell proliferation and neurogenesis in the hippocampus of mice (During et al., 2003; Hamilton et al., 2011; Hunter & Holscher, 2012; Li et al., 2010; McClean et al., 2011; Parthsarathy & Holscher, 2013a; Porter, Irwin, et al., 2010; Porter, Kerr, et al.,…”
BackgroundSelf-citationInsulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation
Schubert, M., Brazil, D. P., Burks, D. J., Kushner, J. A., Ye, J., Flint, C. L., Farhang-Fallah, J., Dikkes, P., Warot, X. M., Rio, C., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-18-07084.2003 · Cited by 488
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Type 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Inflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
Varvel, N. H., Neher, J. J., Bosch, A., Wang, W., Ransohoff, R. M., Miller, R. J., & Dingledine, R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604263113 · Cited by 357 · cited 1×
“…present in the brains of people with Alzheimer's disease (Akiyama et al., 2000; Clark & Vissel, 2014), Parkinson's disease (Hirsch & Hunot, 2009; Tansey & Goldberg, 2010), stroke (Endres et al., 2008), epilepsy (Varvel et al., 2016), Huntington chorea (Ghasemi, Dargahi, et al., 2013) and others.”
Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321 · cited 2×
“Several novel dual agonists have been tested in clinical trials in patients with type 2 diabetes mellitus and some show better effects when compared with single GLP-1 receptor agonists (Finan et al., 2013; Frias et al., 2017, 2018).”
BackgroundCukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30173-3 · Cited by 300
Luchsinger, J. A., Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., Ichise, M., Manly, J., Devanand, D. P., & Bagiella, E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150493 · Cited by 285 · cited 1×
“The results from preclinical studies are mixed (Hölscher, 2020b) and a Phase II clini- cal trial that tested metformin in Alzheimer's disease patients showed no improvement (Luchsinger et al., 2016).”
ResultExenatide Exerts a Potent Antiinflammatory Effect
Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284
Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263 · cited 1×
“Exendin-4 had similar protective effects in the MPTP mouse model of Parkinson's disease (Kim et al., 2009; Li et al., 2009).”
BackgroundLiu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246
Self-citationType 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression
Chohan, H., Senkevich, K., Patel, R. K., Bestwick, J. P., Jacobs, B. M., Bandres Ciga, S., Gan‐Or, Z., & Noyce, A. J. (2021) · Movement Disorders · doi:10.1002/mds.28551 · Cited by 228 · cited 2×
“impairments (Chohan et al., 2021) (see also Cheong et al.”
BackgroundHamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227
Self-citationGlucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207 · cited 2×
“In fact, GLP-1 is considered to be an anti-inflammatory cytokine and reduces release of pro-inflammatory cytokines (Iwai et al., 2006; Kappe et al., 2012).”
BackgroundNyberg, J., Anderson, M. F., Meister, B., Alborn, A.-M., Ström, A.-K., Brederlau, A., Illerskog, A.-C., Nilsson, O., Kieffer, T. J., Hietala, M. A., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4920-04.2005 · Cited by 191
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188 · cited 1×
“DA3-CH showed better BBB penetration, but DA4-JC with a poly-Lys modification crossed the BBB at the highest level (Salameh et al., 2020).”
BackgroundReappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
Self-citationZhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease · doi:10.3233/jpd-181503 · Cited by 173
Self-citationMcClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170 · cited 3×
“In other studies, liraglutide had neuroprotective effects in 14- to 16-month-old APP/PS1 mice, indi- cating that treatment even at more progressed stages of Alzheimer's disease may still have benefits (McClean & Holscher, 2014a).”
BackgroundSelf-citationKuan, Y.-C., Huang, K.-W., Lin, C.-L., Hu, C.-J., & Kao, C.-H. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.002 · Cited by 168 · cited 1×
“…risk of developing Alzheimer's disease (Akimoto et al., 2020; An et al., 2018; Kellar & Craft, 2020; Liu, Hu, et al., 2015) or Parkinson's disease (Athauda & Foltynie, 2016; Hu et al., 2007; Kuan et al., 2017; Rhee et al., 2020; Sergi et al., 2019; Svenningsson et al., 2016) later on in life.”
Sharma, M. K., Jalewa, J., & Hölscher, C. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12469 · Cited by 151
Self-citationGault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125 · cited 1×
“Studies in animals with type 2 diabetes mellitus have shown an added benefit of GIP analogues when added to GLP-1 analogues to control blood glu- cose levels (Gault et al., 2011).”
BackgroundRhee, S. Y., Han, K.-D., Kwon, H., Park, S.-E., Park, Y.-G., Kim, Y.-H., Yoo, S.-J., Rhee, E.-J., & Lee, W.-Y. (2020) · Diabetes Care · doi:10.2337/dc19-0760 · Cited by 109 · cited 2×
“…risk of developing Alzheimer's disease (Akimoto et al., 2020; An et al., 2018; Kellar & Craft, 2020; Liu, Hu, et al., 2015) or Parkinson's disease (Athauda & Foltynie, 2016; Hu et al., 2007; Kuan et al., 2017; Rhee et al., 2020; Sergi et al., 2019; Svenningsson et al., 2016) later on in life.”
BackgroundGLP-1 secretion by microglial cells and decreased CNS expression in obesity
Kappe, C., Tracy, L. M., Patrone, C., Iverfeldt, K., & Sjöholm, Å. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-276 · Cited by 107 · cited 1×
“In fact, GLP-1 is considered to be an anti-inflammatory cytokine and reduces release of pro-inflammatory cytokines (Iwai et al., 2006; Kappe et al., 2012).”
BackgroundSemaglutide: First Global Approval
Dhillon, S. (2018) · Drugs · doi:10.1007/s40265-018-0871-0 · Cited by 104
Yang, X., Feng, P., Zhang, X., Li, D., Wang, R., Ji, C., Li, G., & Hölscher, C. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107748 · Cited by 103 · cited 1×
“Neurogenesis had also been normalised in the dentate gyrus (Yang et al., 2019).”
BackgroundSelf-citationDarsalia, V., Hua, S., Larsson, M., Mallard, C., Nathanson, D., Nyström, T., Sjöholm, Å., Johansson, M. E., & Patrone, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103114 · Cited by 92 · cited 1×
“The inflammation response in the brain was reduced, too (Darsalia et al., 2014).”
BackgroundSalles, G. N., Calió, M. L., Hölscher, C., Pacheco-Soares, C., Porcionatto, M., & Lobo, A. O. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107813 · Cited by 71 · cited 1×
“Other studies were able to repro- duce the protective effects of liraglutide in mouse models of Alzheimer's disease (Holubova et al., 2018; Parthsarathy & Holscher, 2013a; Qi et al., 2016; Salles et al., 2020).”
Self-citationBasalay, M. V., Davidson, S. M., & Yellon, D. M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06915-8 · Cited by 68 · cited 2×
“respectively and improved motor scores at 72-h post-surgery (Basalay et al., 2019).”
BackgroundGlucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation
Dozier, K. C., Cureton, E. L., Kwan, R. O., Curran, B., Sadjadi, J., & Victorino, G. P. (2009) · Peptides · doi:10.1016/j.peptides.2009.06.019 · Cited by 58 · cited 1×
“…can reduce monocyte adhe- sion to the aortic endothelium in an inflammation response in athero- sclerosis and also prevents lipopolysaccharide (LPS)-induced cytokine and chemokine release (Arakawa et al., 2010) and can prevent an increase in microvascular permeability (Dozier et al., 2009).”
BackgroundChen, F., Wang, W., Ding, H., Yang, Q., Dong, Q., & Cui, M. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0661-0 · Cited by 52
Maskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20952011 · Cited by 51 · cited 2×
“For further details on this topic, please consult the reviews (Darsalia et al., 2018; Erbil et al., 2019; Groeneveld et al., 2016; Maskery et al., 2021).”
BackgroundLi, L., Zhang, L.-Y., Jin, Q.-Q., & Hölscher, C. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.303045 · Cited by 38
Self-citation
Research works printed but not linked: 145
- 10.1007/s00210-018-1497-1 · DOI
- 10.1038/nrn812 · DOI · Paper page
- 10.1016/S1474-4422(02)00133-3 · DOI · Paper page
- 10.1177/1533317519899546 · DOI · Paper page
- 10.1016/j.amjms.2017.05.002 · DOI
- Alexander S. P. H., 2019, THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors, British Journal of Pharmacology, 176, S21
- Alexander S. P. H., 2019, THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors, British Journal of Pharmacology, 176, S247
- Alexander S. P. H., 2019, THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels, British Journal of Pharmacology, 176, S142
- 10.1016/j.jalz.2017.09.011 · DOI · Paper page
- 10.1007/s00702-009-0272-3 · DOI
- 10.1016/j.pneurobio.2016.10.001 · DOI · Paper page
- 10.1001/jamaneurol.2018.4304 · DOI · Paper page
- 10.3233/JPD-140364 · DOI · Paper page
- 10.1016/j.freeradbiomed.2004.04.007 · DOI
- 10.3390/ijms18112493 · DOI · Paper page
- 10.1007/s11011-017-0059-4 · DOI
- 10.1002/path.5056 · DOI · Paper page
- 10.1073/pnas.0901402106 · DOI · Paper page
- 10.3233/JAD-180808 · DOI · Paper page
- 10.1016/j.neuroscience.2014.02.022 · DOI
- 10.4239/wjd.v6.i6.807 · DOI · Paper page
- 10.1097/WNR.0000000000000548 · DOI · Paper page
- 10.1016/j.ejphar.2018.03.024 · DOI
- 10.1007/s11064-017-2250-8 · DOI
- 10.3233/JPD-191900 · DOI · Paper page
- 10.1054/npep.1999.0757 · DOI
- 10.1038/ijo.2015.136 · DOI
- 10.1016/j.brainresbull.2019.08.001 · DOI
- 10.1124/pr.112.005850 · DOI
- 10.1186/1742-2094-11-51 · DOI · Paper page
- 10.1111/bph.14471 · DOI
- 10.3233/JAD-141791 · DOI · Paper page
- 10.1196/annals.1332.005 · DOI · Paper page
- 10.1016/j.molmet.2015.07.008 · DOI · Paper page
- 10.1111/j.1464-5491.2008.02484.x · DOI · Paper page
- 10.1016/j.neurobiolaging.2005.08.021 · DOI · Paper page
- 10.1001/archneurol.2011.233 · DOI · Paper page
- Dailey G. E., 2007, Using prandial insulin to achieve glycemic control in type 2 diabetes, The Journal of Family Practice, 56, 735
- 10.1016/j.neuropharm.2017.08.022 · DOI · Paper page
- 10.1042/CS20110374 · DOI · Paper page
- 10.2337/db12-0988 · DOI · Paper page
- 10.3389/fneur.2018.00292 · DOI · Paper page
- 10.1016/j.biopha.2018.10.066 · DOI · Paper page
- 10.1016/S0531-5565(00)00149-2 · DOI
- 10.1016/j.pharmthera.2006.11.007 · DOI · Paper page
- 10.1016/j.neuroscience.2012.10.045 · DOI
- Edison P. Femminella G. Frangou E. Love S. Busza G. Holmes C. Ritchie C. Lawrence R. McFarlane B. Tadros G. Ridha B. H. &Bannister C.(2020).Evaluating the effects of the novel GLP‐1 analogue liraglutide in Alzheimer's disease (ELAD study). CTAD conference 2020 abstract OC30.
- Egefjord L., 2012, Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease ‐ protocol for a controlled, randomized double‐blinded trial, Danish Medical Journal, 59, A4519
- 10.1159/000118039 · DOI · Paper page
- 10.1080/02699052.2019.1587000 · DOI · Paper page
- 10.3233/JAD-121888 · DOI · Paper page
- 10.1186/alzrt174 · DOI · Paper page
- 10.1186/s13063-019-3259-x · DOI · Paper page
- 10.1016/j.neuropharm.2018.02.012 · DOI
- 10.4061/2011/436813 · DOI · Paper page
- 10.1097/FBP.0b013e32833c8544 · DOI
- 10.1177/1479164118788079 · DOI · Paper page
- 10.1007/s40263-013-0076-8 · DOI · Paper page
- 10.1111/j.1749-6632.1999.tb07839.x · DOI · Paper page
- 10.1007/s12035-013-8404-z · DOI
- 10.1007/s12035-012-8339-9 · DOI · Paper page
- 10.1002/cne.24905 · DOI · Paper page
- 10.1186/1742-2094-5-3 · DOI · Paper page
- 10.1111/jdi.12420 · DOI · Paper page
- 10.1002/jnr.22565 · DOI · Paper page
- 10.1097/WNR.0000000000000490 · DOI · Paper page
- 10.1016/j.brainres.2015.12.052 · DOI
- 10.1371/journal.pone.0158205 · DOI · Paper page
- 10.3233/JAD-143090 · DOI · Paper page
- 10.1186/1742-2094-5-19 · DOI · Paper page
- 10.1042/BST0390891 · DOI · Paper page
- 10.1042/BST20140016 · DOI · Paper page
- 10.1016/j.neuropharm.2018.01.040 · DOI · Paper page
- 10.3389/fnagi.2019.00088 · DOI · Paper page
- Hölscher C., 2020, International review of neurobiology: Metabolic drivers and bioenergetic components of neurodegenerative disease, 65
- 10.1016/j.neuropharm.2018.11.002 · DOI · Paper page
- 10.1007/978-3-7091-7508-8_18 · DOI · Paper page
- 10.1016/j.ejphar.2004.02.049 · DOI · Paper page
- 10.1007/BF00314304 · DOI · Paper page
- 10.1016/j.neuropharm.2017.02.013 · DOI
- 10.1111/jnc.13736 · DOI · Paper page
- 10.1515/revneuro-2015-0021 · DOI · Paper page
- 10.1016/j.brainres.2015.09.035 · DOI
- 10.1002/ddr.21297 · DOI
- 10.1016/0196-9781(94)90016-7 · DOI
- 10.1016/j.neuropharm.2018.02.027 · DOI
- 10.1016/j.neuropharm.2017.11.015 · DOI · Paper page
- 10.1007/s11064-016-1890-4 · DOI
- 10.1007/s11010-016-2678-1 · DOI
- 10.1002/jnr.22596 · DOI · Paper page
- 10.3233/JAD-2006-9102 · DOI · Paper page
- Li C., 2020, The novel GLP‐1/GIP analogue DA5‐CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD, Brain and Behavior: A Cognitive Neuroscience Perspective, 10, e01505, 10.1002/brb3.1505 · DOI · Paper page
- 10.1186/s12868-016-0272-9 · DOI · Paper page
- 10.3233/JAD-2010-1314 · DOI · Paper page
- 10.1016/j.neuropharm.2015.10.002 · DOI
- 10.1016/j.ejphar.2016.11.050 · DOI
- 10.1523/JNEUROSCI.5180-14.2015 · DOI · Paper page
- 10.3389/fphar.2020.00136 · DOI
- 10.1007/s12017-012-8199-5 · DOI
- 10.1016/j.cmet.2013.11.002 · DOI · Paper page
- 10.1023/A:1007627725251 · DOI
- 10.1111/j.1463-1326.2011.01357.x · DOI · Paper page
- 10.1177/1533317520953041 · DOI · Paper page
- 10.1016/j.neuropharm.2013.08.005 · DOI · Paper page
- 10.1016/j.bbr.2015.07.024 · DOI
- 10.1002/(SICI)1096‐9861(19990111)403:2<261::AID‐CNE8>3.0.CO;2‐5 · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
- 10.1016/0361-9230(92)90068-9 · DOI
- 10.1007/BF00313602 · DOI · Paper page
- 10.3233/JAD-180578 · DOI · Paper page
- 10.1371/journal.pone.0214364 · DOI · Paper page
- 10.1002/jnr.21349 · DOI · Paper page
- 10.11648/j.ajbio.20150301.13 · DOI
- 10.3390/ijms22020860 · DOI · Paper page
- 10.3233/JAD-180584 · DOI · Paper page
- 10.1038/s41598-017-16488-x · DOI · Paper page
- 10.1371/journal.pone.0065420 · DOI
- 10.1371/journal.pone.0058784 · DOI · Paper page
- 10.1016/j.ejphar.2012.12.012 · DOI · Paper page
- 10.1016/j.ejphar.2010.10.059 · DOI
- 10.1111/j.1463-1326.2010.01259.x · DOI · Paper page
- 10.1016/j.ejphar.2016.04.052 · DOI
- 10.1016/0166-2236(95)93890-A · DOI · Paper page
- 10.1016/j.neuropharm.2017.11.016 · DOI
- 10.1111/dom.12269 · DOI · Paper page
- 10.3389/fnagi.2019.00302 · DOI · Paper page
- 10.1016/j.bbr.2017.03.032 · DOI
- 10.1002/mds.26734 · DOI
- 10.2217/nmt.13.73 · DOI · Paper page
- Talbot K.(2021).Direct demonstration of brain insulin resistance in Alzheimer's and Parkinson's disease dementia and its alleviation with incretin receptor agonists. AD/PD 2021 conference Boston USA
- 10.1038/jcbfm.2011.51 · DOI · Paper page
- 10.1210/endo.133.6.8243312 · DOI · Paper page
- 10.1080/14728222.2018.1487952 · DOI · Paper page
- 10.1016/j.ejphar.2017.03.059 · DOI
- 10.1016/j.eplepsyres.2018.03.009 · DOI
- 10.1016/j.bbr.2018.08.006 · DOI · Paper page
- 10.1523/ENEURO.0053-14.2015 · DOI · Paper page
- 10.3390/ijms20051050 · DOI · Paper page
- 10.3390/ijms19041153 · DOI
- 10.1016/j.ejphar.2017.06.029 · DOI
- 10.1016/j.npep.2018.07.003 · DOI · Paper page
- 10.3233/JPD-191768 · DOI · Paper page
- 10.1016/j.bbr.2015.07.021 · DOI
- 10.1016/j.peptides.2019.170184 · DOI · Paper page
- 10.1016/j.bbrc.2019.01.103 · DOI · Paper page
- 10.1038/srep26859 · DOI · Paper page
Cited by
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Self-citationTrapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154
“Although this topic is reviewed in detail by another article within this themed issue (Hölscher, 2021), we would like to briefly consider the following points.”
BackgroundAnti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
“to trigger an inflammatory response in the brain to increase its density, which indicates that it plays a role in controlling inflammation [22,91].”
BackgroundWang, Z.-J., Li, X.-R., Chai, S.-F., Li, W.-R., Li, S., Hou, M., Li, J.-L., Ye, Y.-C., Cai, H.-Y., Hölscher, C., et al. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109716 · Cited by 125
Self-citationTargeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
Meurot, C., Jacques, C., Martin, C., Sudre, L., Breton, J., Rattenbach, R., Bismuth, K., & Berenbaum, F. (2022) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2022.02.001 · Cited by 94
Metadata
- Authors
- Hölscher, C.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2021-05-29
- Volume
- 179
- Issue
- 4
- Pages
- 695-714
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W3159277791
- Cited by
- 145
- References
- 58
- FWCI
- 11.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.